NeoGenomics Raises 2026 Revenue Guidance Amid Strong Clinical and NGS Growth
NeoGenomics (NEO) has raised its 2026 revenue guidance to a range of $807 million to $809 million, driven by robust performance in key segments. During the Q3 earnings call, management highlighted a 13% year-over-year increase in clinical revenue and a significant 29% surge in Next-Generation Sequencing (NGS) revenue. The company also reported an expansion of adjusted gross margins by over 300 basis points. While the financial outlook is strengthening, the company announced a planned leadership transition with the current CEO scheduled to step down in January 2027.
Tickers: $NEO
Topics: clinical revenue gross margin expansion NGS revenue revenue growth